United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Pfizer just released 2024 earnings forecasts that fell short of analysts' estimates. Lower demand for coronavirus products is weighing on earnings and the stock price.

Should You Worry About the Latest Wave of Bad News from Pfizer?

Archer-Daniels-Midland Company

Baker Hughes Co

CVS Health

Dow Inc

Energy Transfer LP Unit

Ford Motor Company

Kroger

MetLife

Philip Morris

Southern Company

Verizon

Exxon Mobil

The Summer 2023 edition of Fortune Magazine revealed 500 biggest U.S. companies by revenue. Dogcatcher's quest to sniff out the best dividend buys focused on 68 industry leaders using YCharts 12/14/23 data. Those 68 industry leaders were segmented into 21 business sectors, ranging (alphabetically) from apparel to wholesalers. 3 of the 68 were private or foreign exchange listed firms not tracked by YCharts, leaving 65 listed. 58 dividend yielding stocks led those 68 industry leaders and ranged 0.17% to 9.08% in annual yield and ranged -15.07% to 36.4% in broker estimated one-year price target upsides by YCharts 12/14/23 reckoning.

4 Ideal December Dividend Fortune 500 Industry Leaders (Of 68)

PFE has squandered the COVID-19 windfall by overpaying for Seagen, while contributing to the deterioration of its balance sheet and the eventual plunge in its stock prices. We believe that its inventory write-downs and goodwill amortization may accelerate in the near-term, thanks to the impacted COVID demand and expensive acquisitions, respectively. The combination of underwhelming FY2024 guidance and patent cliff/ Medicare headwinds from 2026 onwards do not bode well to PFE's intermediate term prospects as well.

Pfizer: The Bears Have Won This Round

Pfizer doesn't have a great track record in the stock market over the past 20 years. However, the company has substantially revamped its business recently.

Could Pfizer Stock Help You Become a Millionaire?

Hasbro

Macy's

Here are some of the major companies whose stocks moved on the week's news.

The Score: Macy's, Hasbro, Pfizer and More Stocks That Defined the Week

– PADCEV plus pembrolizumab approved based on groundbreaking EV-302 trial – – Confirmatory trial found PADCEV plus pembrolizumab nearly doubled median overall survival compared to standard of care platinum-based chemotherapy – TOKYO and NEW YORK , Dec. 15, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE:4503, President and CEO: Naoki Okamura, "Astellas") and Pfizer Inc. (NYSE: PFE) today announced that on December 15, 2023 the U.S. Food and Drug Administration (FDA) has approved PADCEV® (enfortumab vedotin-ejfv, an antibody-drug conjugate [ADC]) with KEYTRUDA® (pembrolizumab, a PD-1 inhibitor) for the treatment of adult patients with locally advanced or metastatic urothelial cancer (la/mUC). This combination is the first approved to offer an alternative to platinum-containing chemotherapy, the current standard of care in first-line la/mUC.

PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) Approved by FDA as the First and Only ADC Plus PD-1 to Treat Advanced Bladder Cancer

Pfizer, Inc. stock has fallen nearly 60% from its peak in December 2021. Could a turnaround be near? In a promising sign, Pfizer has announced its 14th consecutive annual dividend increase, signaling confidence in its ability to cover payments. Pfizer stock is trading at a favorable valuation compared to its peers and has potential for upside, with a median price target of $32.

Pfizer: Dividend Boost At The Right Time

Another analyst cut estimates on Pfizer stock on Friday after the pharma heavyweight, earlier this week, issued a disappointing 2024 guide.

The Pain Continues For Bedraggled Pharma Heavyweight Pfizer

For Pfizer (NYSE: PFE) investors, 2023 has been a tumultuous journey, marked by a nearly 50% decline in the stock – making it the drugmaker's worst-performing year on record.

Here's how much a $10k investment in Pfizer stock 5 years ago is now worth

Alibaba

JPMorgan Chase & Co

Walgreens

Here's a quick economics lesson to return to the good old college days. When markets think that a country's GDP is set to grow in the future, they will turn bullish (massively bullish) toward equity markets.

Quick list of bargain stocks to end the year

Abbott Labs

Moderna

Investors loved these stocks earlier in the pandemic -- but they've since fallen out of favor. They actually make terrific long-term buys, though, and today you can pick them up for a steal.

3 No-Brainer Healthcare Stocks to Buy Right Now

The drugmaker is pulling back on some of its research programs and laying off workers after overestimating pandemic-product sales.

Pfizer Helped Save the World With Covid Vaccines. Now It Needs to Right Itself.

Nona Biosciences will receive a total of up to $53 Million in upfront and near-term payments, with the potential for milestones of up to $1.05 billion plus royalties. Pfizer partnership expands Nona's global network of collaborations, reinforcing its commitment to providing cutting-edge technology innovation to novel therapeutics development.

Nona Biosciences Enters into a Global License Agreement with Pfizer for HBM9033, an MSLN-Targeted Antibody-Drug Conjugate (ADC)

Pfizer Inc. PFE, -1.99% said late Thursday that its board of directors declared an increase in the company's quarterly dividend to 42 cents a share, from 41 cents a share. The dividend is payable March 1 to holders of record on Jan. 26.

Pfizer increases dividend by one penny to 42 cents a share

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared an increase in the quarterly cash dividend on the company's common stock to $0.42 for the first-quarter 2024 dividend, payable March 1, 2024, to holders of the Common Stock of record at the close of business on January 26, 2024. The first-quarter 2024 cash dividend will be the 341st consecutive quarterly dividend paid by Pfizer. “We are pleased to increase our quarterly dividend, which repres.

Pfizer Declares First-Quarter 2024 Dividend

Lithium Americas Corp

Year-end tax-selling and institutional window-dressing create opportunities to buy beaten-down quality companies. Lithium Americas and Pfizer are two companies that have hit their 12-month lows and are considered viable with potential for future growth. LAC owns the largest known lithium mining property in the US, while PFE has a strong cash flow and a diverse pharmaceutical pipeline.

Fallen Angels, Part II: The Dodgeball 7

AMC Entertainment

Investors looking for solid companies that offer a reliable source of growth may want to avoid the companies I'm listing below. They've all struggled with reduced cash flow, lower-than-expected full-year guidance, and possible bankruptcy.

3 Stocks That Are About to Get Absolutely Crushed

Sponsored: Tips for Investing A financial advisor can help you understand the advantages and disadvantages of investment properties.

6 Reasons to Avoid Pfizer (PFE) Stock Without Hesitation

Pfizer's (PFE) shares decline almost 7% in response to the muted guidance for 2024. Revenues are expected to be in the range of $58.5 to $61.5 billion, while adjusted EPS is expected in the range of $2.05 to $2.25.

Pfizer (PFE) Stock Sinks on Weak 2024 View as COVID Sales Fall

Enbridge

AT&T

Pfizer's valuation has taken a beating this year as its sales slumped 42% last quarter. Falling oil prices and a big acquisition have made this a disappointing year for Enbridge.

Are These 3 Cheap Dividend Stocks With High Yields Too Good to Be True?

Seagen

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of Seagen Inc. (NASDAQ: SGEN), a global biotechnology company that discovers, develops and commercializes transformative cancer medicines. Pfizer completed its acquisition of all outstanding common stock of Seagen for $229 in cash per share, for a total enterprise value of approximately $43 billion. “Cancer remains a leading cause of death, and one in three people in the U.S. will rec.

Pfizer Completes Acquisition of Seagen

After surging to unprecedented peaks in 2021, Pfizer Inc. (NYSE: PFE) faced extreme challenges in 2023, marking a significant downturn for the world's largest drugmaker.

Pfizer stock trades at 10-year low; PFE to crash to $20?

Shares of Pfizer recently fell hard after the company announced full-year 2024 guidance. Pfizer also received regulatory approval to complete its proposed $43 billion acquisition of Seagen.

Pfizer's 2024 Outlook Disappointed Wall Street, But Where Will the Stock Be in 5 Years?

Editor's note: William Canestaro is managing director at Seattle venture capital firm WRF Capital and leads the biotechnology investment team.

How Pfizer's $43B acquisition of Seagen may impact Seattle and broader biotech market

Vertex Pharmaceuticals

U.S. equities were slightly higher at midday ahead of comments from the Federal Reserve following its last meeting of the year. It's expected the central bank won't raise interest rates any further to fight inflation, and investors will also be paying attention to whether policymakers indicate any rate cuts might be coming.

News for Pfizer Stock (PFE)